This is the authors' abstract. We don't add key points for this paper.
PURPOSE: To subject a number of areas of contention in the myopia field to evidence-based scrutiny. METHOD: The 10 topics from our previous review were revisited, and nine new topics were also critiqued with emphasis on the recent peer-reviewed literature. RESULTS: The following observations were made: 0.01% atropine should not be considered a frontline myopia control treatment; the role of relative peripheral hyperopia in myopia development and progression remains unclear; undercorrection probably does not slow myopia progression; treatment efficacy diminishes with time; percentage is a misleading metric of efficacy; handheld digital devices have not been proven to be myopiagenic; more time outdoors may slow myopic shift to a similar extent in children with and without myopia; daylight is responsible for only part of the impact of outdoor time; all myopia, not just high myopia, carries the risk of visually threatening complications; premyopia is a real condition. Furthermore, myopia may be considered a disease; accommodation lag may be a measurement artifact; adult myopia progression is significant; past progression is a flawed indicator to initiate myopia control; fast progression does not mean nonresponse to treatment; single vision soft contact lenses are not myopiagenic; red light therapy may not be safe; contact lens wear in children may be considered safe; rebound cannot be assessed by comparing progression during and following treatment. CONCLUSIONS: The myopia field continues to evolve with some conflicts resolved, ongoing areas of confusion, and new uncertainties emerging.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Brennan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: